USA remote
Senior Director, Patient Reported Outcomes
About this role
Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide.
Our people are united by a shared way of working: follow the science, challenge assumptions, act with urgency and hold ourselves to a high standard of rigor—all in service of patients. The Opportunity: The Senior Director, Patient-Reported Outcomes (PRO) provides scientific and strategic expertise for the integration of patient-centered outcomes into clinical development programs. This individual serves as a key PRO subject matter expert and leads the development and execution of PRO strategies for assigned programs in support of clinical development, regulatory, market access, and scientific communication objectives.
Working closely with Clinical Development, Biostatistics, Regulatory Affairs, Medical Affairs, Clinical Operations, and other cross-functional partners, the Senior Director will translate patient-centered evidence needs into practical study plans and deliverables from development through registration and lifecycle management. This role is initially an individual contributor position with the opportunity to assume people-management responsibilities as the organization grows.
Key responsibilities include: Develop and lead PRO strategy for assigned clinical development programs, ensuring alignment with clinical, regulatory, and market access objectives. Recommend and support the selection, implementation, validation, and interpretation of PRO measures and patient-centered endpoints, including fit-for-purpose assessment of existing instruments. Partner with cross-functional teams to incorporate PRO objectives and assessments into study designs, protocols, schedules of assessments, statistical analysis plans, regulatory documents, and publications.